hematide

09/01/2008 - "Hematide is undergoing phase III clinical trials for anemia."
09/01/2008 - "In conclusion, these results support the use of repeated administration of hematide for the correction of anemia."
08/01/2007 - "Hematide corrected antibody-induced anemia in a rat PRCA model. "
10/01/2006 - "Hematide was able to alleviate anemia in an experimental CRI rodent model. "
10/01/2006 - "Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia."

09/15/2006 - "These results support phase 2 studies in patients with anemia associated with chronic kidney disease or cancer and suggest that Hematide administered as infrequently as once a month may result in a sustained elevation of Hgb levels. "
05/01/2007 - "Recent data on anemia management in chronic kidney disease (CKD) patients and the results with new drugs for the treatment of renal anemia that are under development, such as the continuous erythropoietin receptor activator (CERA) or Hematide were presented. "
10/01/2006 - "To evaluate the preclinical erythropoiesis stimulating properties of Hematide, a novel, PEGylated, synthetic peptide for the treatment of anemia associated with chronic kidney disease and cancer. "
01/01/2012 - "Recently, a new erythropoiesis-stimulating agent, peginesatide (Omontys, formerly referred to as Hematide), belonging to the upcoming class of EPO-mimetic peptides, received approval for the treatment of anaemia in humans with chronic kidney disease on dialysis. "
08/01/2007 - "To evaluate the potential of Hematide, a PEGylated, synthetic peptide-based erythropoiesis-stimulating agent that is in clinical development for the treatment of anemia associated with chronic kidney disease and cancer, to correct antierythropoietin antibody-associated pure red cell aplasia (PRCA). "

09/15/2006 - "These results support phase 2 studies in patients with anemia associated with chronic kidney disease or cancer and suggest that Hematide administered as infrequently as once a month may result in a sustained elevation of Hgb levels. "
10/01/2006 - "To evaluate the preclinical erythropoiesis stimulating properties of Hematide, a novel, PEGylated, synthetic peptide for the treatment of anemia associated with chronic kidney disease and cancer. "
09/15/2006 - "Hematide is an investigational pegylated synthetic peptide that stimulates erythropoiesis in animal models and is being developed for the treatment of anemia associated with chronic renal failure and cancer. "
08/01/2007 - "To evaluate the potential of Hematide, a PEGylated, synthetic peptide-based erythropoiesis-stimulating agent that is in clinical development for the treatment of anemia associated with chronic kidney disease and cancer, to correct antierythropoietin antibody-associated pure red cell aplasia (PRCA). "

02/01/2009 - "In conclusion, Hematide is a potent erythropoiesis-stimulating agent, and the studies provide support for the safety of clinical development, including chronic dosing, for the treatment of anaemia associated with chronic renal failure."
01/01/2010 - "Hematide is a synthetic PEGylated peptidic erythropoiesis stimulating agent (ESA) that is presently being developed for the correction of anemia in patients with chronic renal failure. "
02/01/2009 - "Hematide is a synthetic peptide-based, PEGylated erythropoiesis-stimulating agent, which is being developed for the chronic treatment of anaemia associated with chronic renal failure. "
09/15/2006 - "Hematide is an investigational pegylated synthetic peptide that stimulates erythropoiesis in animal models and is being developed for the treatment of anemia associated with chronic renal failure and cancer. "

04/01/2010 - "In conclusion, the Hematide-associated adverse findings were attributed to exaggerated erythropoiesis (pronounced and prolonged polycythemia) resulting from administration of an ESA to pregnant animals."
04/01/2010 - "Hematide induced pronounced polycythemia in all Hematide-treated dams. "
02/01/2009 - "The primary pharmacology of Hematide resulted in erythroid polycythemia as measured by elevated haemoglobin levels that were time- and dose-dependent. "
09/01/2008 - "Hematide administration was associated with time and dose-dependent polycythemia. "
01/01/2008 - "The pharmacological action of Hematide resulted in polycythemia. "